ArticleAnalytical and bioanalytical chemistry2011
Analysis of E. coli K5 capsular polysaccharide heparosan.
Article in Analytical and bioanalytical chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 55 citations in OpenAlex.
- Advances in chemoenzymatic synthesis of glycosaminoglycans and proteoglycans.Current opinion in chemical biology · 2026Review
- Coupling optimization of cell growth cycle and key enzyme membrane localization for enhanced synthesis of high molecular weight heparosan by Corynebacterium glutamicum.Bioresources and bioprocessing · 2025Article
- Synthetic biology design principles enable efficient bioproduction of Heparosan with low molecular weight and low polydispersion index for the biomedical industry.Synthetic biology (Oxford, England) · 2025Article
- Structural and mechanistic characterization of bifunctional heparan sulfate N-deacetylase-N-sulfotransferase 1.Nature communications · 2024Article
- Simultaneous production ofHeliyon · 2023Article
- Imaging ofScience advances · 2023Article
- The construction of a dual-functional strain that produces both polysaccharides and sulfotransferases.Biotechnology letters · 2021Article
- Complete biosynthesis of a sulfated chondroitin in Escherichia coli.Nature communications · 2021Article
- High density fermentation of probiotic E. coli Nissle 1917 towards heparosan production, characterization, and modification.Applied microbiology and biotechnology · 2021Article
- Tools for the Quality Control of Pharmaceutical Heparin.Medicina (Kaunas, Lithuania) · 2019Review
- Metabolic engineering of Bacillus megaterium for heparosan biosynthesis using Pasteurella multocida heparosan synthase, PmHS2.Microbial cell factories · 2019Article
- Roles of two types of heparan sulfate clusters in Wnt distribution and signaling in Xenopus.Nature communications · 2017Article
- Engineered heparins as new anticoagulant drugs.Bioengineering & translational medicine · 2017Review
- Cyclic AMP (cAMP) Receptor Protein-cAMP Complex Regulates Heparosan Production in Escherichia coli Strain Nissle 1917.Applied and environmental microbiology · 2015Article
- Masquerading microbial pathogens: capsular polysaccharides mimic host-tissue molecules.FEMS microbiology reviews · 2014Review
- Sequence analysis and domain motifs in the porcine skin decorin glycosaminoglycan chain.The Journal of biological chemistry · 2013Article
- Draft Genome Sequence of Escherichia coli Strain Nissle 1917 (Serovar O6:K5:H1).Genome announcements · 2013Article
- Draft Genome Sequence of Escherichia coli Strain ATCC 23506 (Serovar O10:K5:H4).Genome announcements · 2013Article
- Molecular Mass Characterization of Glycosaminoglycans with Different Degrees of Sulfation in Bioengineered Heparin Process by Size Exclusion Chromatography.Current analytical chemistry · 2012Article
- Proteoglycan sequence.Molecular bioSystems · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Heparosan is the key precursor for the preparation of bioengineered heparin, a potential replacement for porcine intestinal heparin, an important anticoagulant drug. The molecular weight (MW) distribution of heparosan produced by the fermentation of E. coli K5 was investigated. Large-slab isocratic and mini-slab gradient polyacrylamide gel electrophoresis (PAGE) were used to analyze the MW and polydispersity of heparosan. A preparative method that allowed fractionation by continuous-elution PAGE was used to obtain heparosan MW standards. The MWs of the heparosan standards were determined by electrospray ionization Fourier-transform mass spectrometry (ESI-FT-MS). A ladder of the standards was then used to determine the MW properties of polydisperse heparosan samples. Unbleached and bleached heparosan produced by fermentation of E. coli K5 had similar number-averaged MWs (M(N)), weight-averaged MWs (M(W)), and MW ranges of 3,000 to 150,000 Da.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.